Tocilizumab Plus Remdesivir to Be Evaluated for Severe COVID-19 Pneumonia
The trial is being conducted by Roche in collaboration with Gilead Sciences.
Emerging Diseases
Interim Data on Abbott ID NOW COVID-19 Rapid Test Performance Announced
An ongoing clinical study of the Abbott ID NOW™ COVID-19 rapid test shows strong agreement to lab-based molecular polymerase chain reaction (PCR) instruments.
High Dose IVIG to Be Investigated for Severe COVID-19 in Phase 3 Trial
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Phase 3 Trial Assessing Ciclesonide Inhalation Aerosol for COVID-19 Underway
The study will enroll 400 patients with symptomatic coronavirus disease 201.
Antiviral Merimepodib to Be Investigated in Phase 2 Trial for COVID-19
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
FDA Authorizes At-Home Sample Collection Kit for Use With Multiple COVID-19 Diagnostics
The kit will be available only by prescription to individuals who have been screened using an online questionnaire that is reviewed by a healthcare provider.
Umbilical Cord Stem Cell Therapy to Be Assessed in Severe COVID-19
The FDA has approved a phase 1/2a study evaluating the use of umbilical cord mesenchymal stem cells for the treatment of patients with severe cases of COVID-19.
Moderna’s COVID-19 Vaccine Candidate Gets Fast Track Designation
The FDA has granted Fast Track designation to the vaccine candidate, mRNA-1273 (Moderna), against the novel coronavirus (SARS-CoV-2).
FDA Greenlights Study to Evaluate Opaganib in Patients With Moderate to Severe COVID-19
The FDA has approved the Investigational New Drug (IND) application for the phase 2a study of opaganib (RedHill Biopharma) in patients with confirmed moderate to severe SARS-CoV-2 infection.
Triple Antiviral Therapy Looks Promising for Mild to Moderate COVID-19
Treatment with interferon beta-1b in combination with lopinavir/ritonavir and ribavirin was found to be safe and superior to lopinavir/ritonavir alone for reducing the duration of viral shedding and hospital stay in adults with COVID-19.
